Opinion|Videos|February 7, 2025

Navigating CLL Treatment Choices

Panelists discuss the factors considered when selecting between BTK inhibitors and venetoclax plus obinutuzumab for chronic lymphocytic leukemia (CLL), the considerations for choosing among acalabrutinib, zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.

  1. What factors do you consider when selecting between BTK inhibitors and venetoclax plus obinutuzumab for CLL?
  2. If selecting a BTK inhibitor, what factors do you consider when selecting among acalabrutinib, zanubrutinib, and ibrutinib?
  3. With the availability of targeted therapies, what role does cytotoxic chemotherapy play in the treatment of CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo